Company's Proprietary Technology Adopted in 16% of U.S. Cardiology Offices
and Underscores Growing ICG Acceptance and Clinical Importance
SAN DIEGO, Feb. 19 /PRNewswire-FirstCall/ -- CardioDynamics (Nasdaq: CDIC), the innovator and leader of BioZ(R) impedance cardiography (ICG) technology, today announced that the Company's BioZ ICG technology is featured in American College of Cardiology's ACCEL audio series.
ACCEL is the American College of Cardiology's monthly audio series distributed to thousands of cardiologists with the latest cardiovascular news on diagnosis, treatment, and research. This is the first time that ICG has been the subject of an ACCEL interview. Dr. John Schroeder, Professor of Medicine, Stanford University School of Medicine, Stanford, California, is interviewed by the editor of ACCEL, Dr. Richard Conti and discusses ICG technology, validity, and a number of clinical studies which highlight ICG's clinical utility in high blood pressure shortness of breath and heart failure patients.
Michael K. Perry, CardioDynamics Chief Executive Officer, stated, "We are extremely pleased that the American College of Cardiology would elect to highlight ICG on its ACCEL monthly audio series and believe it validates the widespread use of our technology in cardiology offices and its importance in the care of cardiac patients. The interview is very favorable in our judgment, and we hope it will help further increase awareness of ICG among cardiologists."
BioZ ICG technology is available in approximately one out of every six (16%) of cardiology offices as well as one out of every five (20%) outpatient heart failure clinics in the United States. Over one million patient applications are performed annually.
John Schroeder, M.D., F.A.C.C., Professor of Medicine, Stanford
University School of Medicine, Stanford, California, stated, "As a
clinician at an academic institution, I was pleased to be interviewed on
Copyright©2008 PR Newswire.
All rights reserved